Effect of enhanced iron chelation therapy on glucose metabolism in patients with β-thalassaemia major

British Journal of Haematology

Volumn 134, Issue 4, 2006, Pages 438-444

  Farmaki, Kalistheni ^a   Angelopoulos, Nicholas ^b   Anagnostopoulos, George ^a   Gotsis, Efstathios ^c   Rombopoulos, Grigorios ^b   Tolis, George ^b  

^a Korinthos General Hospital   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c Institute Euromedica Encephalos   (Greece)

Author keywords

thalassaemia; Combined therapy; Glucose intolerance; Insulin secretion

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; GLUCOSE; INSULIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE ASSAY; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HOMEOSTASIS; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; IRON CHELATION; IRON METABOLISM; LIVER METABOLISM; MALE; NEUTROPENIA; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SECRETION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BETA-THALASSEMIA; BLOOD GLUCOSE; CHELATION THERAPY; CHILD; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSULIN; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES; TREATMENT OUTCOME;

EID: 33746049146     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06203.x     Document Type: Article

References (38)

1. Alymara, V., Bourantas, D., Chaidos, A., Bouranta, P., Gouva, M., Vassou, A., Tzouvara, E. & Bourantas, K.L. (2004) Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematology Journal, 5, 475-479.
2. American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care, 28(Suppl.), 37-42.
3. Angelopoulos, N.G., Goula, A., Dimitriou, E. & Tolis, G. (2005) Reversibility of hypogonadotropic hypogonadism in a patient with the juvenile form of hemochromatosis. Fertility Sterility, 84, 1744.
4. Angelopoulos, N.G., Goula, A., Rombopoulos, G., Kaltzidou, V., Katounda, E., Kaltsas, D. & Tolis, G. (2006a) Hypoparathyroidism in transfusion-dependent patients with β-thalassaemia. Journal of Bone and Mineral Metabolism, 24, 87-93.
5. Angelopoulos, N.G., Goula, A.K., Papanikolaou, G. & Tolis, G. (2006b) Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. Osteoporosis International, 17, 150-155.
6. Angelopoulos, N.G., Katounda, E., Rombopoulos, G., Goula, A., Kaltzidou, V., Kaltsas, D., Ioannis, P. & Tolis, G. (2006c) Evaluation of bone mineral density of the lumbar spine in patients with beta-thalassemia major with dual-energy x-ray absorptiometry and quantitative computed tomography: a comparison study. Journal of Pediatric Hematology and Oncology, 28, 73-78.
7. Angelopoulos, N., Zervas, A., Livadas, S., Adamopoulos, I., Giannopoulos, D., Goula, A. & Tolis, G. (2006d) Reduced insulin secretion in normoglycemic patients with β-thalassaemia major. Diabetic Medicine (in press).
8. Angelopoulos, N., Papanikolaou, G., Noutsou, M., Rombopoulos, G., Goula, A. & Tolis, G. (2006e) Glucose metabolism, insulin secretion and insulin sensitivity in juvenile hemochromatosis. A case report and review of the literature. Experimental and Clinical Endocrinology and Diabetes (in press).
9. Arrigo, T., Crisafulli, G., Meo, A., Sturiale, M., Lombardo, F., Miceli, M., Cucinotta, D. & De Luca, F. (1998) Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major. Journal of Pediatric Endocrinology and Metabolism, 11(Suppl. 3), 863-866.
10. Borgna-Pignatti, C., Cappellini, M.D., De Stefano, P., Del Vecchio, G.C., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A., Romeo, M.A., Zhao, H. & Cnaan, A. (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 107, 3733-3737.
11. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E. & Harris, J.W. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. New England Journal of Medicine, 331, 567-573.
12. Cario, H., Holl, R.W., Debatin, K.M. & Kohne, E. (2003) Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. European Journal of Pediatrics, 162, 139-146.
13. Chern, J.P.S., Lin, K.H., Lu, M.Y., Lin, K.S., Chen, J.D. & Fu, C.C. (2001) Abnormal glucose tolerance in transfusion-dependant beta thalassaemia. Diabetes Care, 24, 850-854.
14. Cunningham, M.J., Macklin, E.A., Neufeld, E.J. & Cohen, A.R. (2004) Complications of b-thalassaemia major in North America. Blood, 104, 34-39.
15. De Sanctis, V., De Ascola, G. & Wonke, B. (1986) The development of diabetes mellitus and chronic liver disease in long-term chelated beta-thalassaemia major patients. Postgraduate Medicine Journal, 62, 831-836.
16. De Sanctis, V., Zurlo, M.G., Senesi, E., Boffa, C., Cavallo, L. & Di Gregorio, F. (1988) Insulin-dependent diabetes in thalassaemia. Archives of Disease in Childhood, 63, 58-62.
17. Gamberini, M.R., Fortini, M., Gilli, G., Terta, M.R. & De Sanctis, V. (1998) Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemia patients. Journal of Pediatric Endocrinology and Metabolism, 11(Suppl. 3), 867-869.
18. Gamberini, M.R., Fortini, M., De Sanctis, V., Gilli, G. & Testa, M.R. (2004) Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatric Endocrinology Reviews, 2(Suppl. 2), 285-291.
19. Hoffbrand, A.V., Cohen, A. & Hershko, C. (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 102, 17-24.
20. Holl, R.W., Buck, C., Cario, H., Wolf, A., Thon, A., Kohne, E. & Debatin, K.M. (1998) Diagnosis of diabetes mellitus in cystic fibrosis and thalassaemia major. Diabetes Care, 21, 671-672.
21. Italian Working Group on Endocrine Complications in Non-endocrine Diseases (1995) Multicenter study on prevalence of endocrine complications in thalassaemia major. Clinical Endocrinology, 42, 581-586.
22. Kattamis, A., Ladis, V., Berdousi, H., Kelekis, N.L., Alexopoulou, E., Papasotiriou, I., Drakaki, K., Kaloumenou, I., Galani, A. & Kattamis, C. (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells, Molecules, and Diseases, 36, 21-25.
23. Link, G., Konijn, A.M., Breuer, W., Cabantchik, Z.I. & Hershko, C. (2001) Exploring the 'iron shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. The Journal of Laboratory and Clinical Medicine, 138, 130-138.
24. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 28, 412-419.
25. Merkel, P.A., Simonson, D.C., Amiel, S.A., Plewe, G., Sherwin, R.S., Pearson, H.A. & Tamborlane, W.V. (1988) Insulin resistance and hyperinsulinemia in patients with thalassaemia major treated by hypertransfusion. New England Journal of Medicine, 318, 809-814.
26. Mourad, F.H., Hoffbrand, A.V., Sheikh-Taha, M., Koussa, S., Khoriaty, A.I. & Taher, A. (2003) Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron-overloaded thalassaemia patients. British Journal of Haematology, 121, 187-189.
27. Ooi, G.C., Khong, P.L., Chan, G.C., Chan, K.N., Chan, K.L., Lam, W., Ng, I. & Ha, S.Y. (2004) Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients. British Journal of Haematology, 124, 385-390.
28. Origa, R., Bina, P., Agus, A., Crobu, G., Defraia, E., Dessi, C., Leoni, G., Muroni, P.P. & Galanello, R. (2005) Combined therapy with deferiprone and desfoerrioxamine in thalassaemia major. Haematologica, 90, 1163-1168.
29. Pappas, S., Donohue, S.M., Denver, A.E., Mohamed-Ali, V., Goubet, S. & Yudkin, J.S. (1996) Glucose intolerance in thalassaemia major is related to insulin resistance and hepatic dysfunction. Metabolism: Clinical and Experimental, 45, 652-657.
30. Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Tanner, M.A., Smith, G.C., Westwood, M.A., Wonke, B. & Galanello, R. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassaemia major patients with asymptomatic myocardial siderosis. Blood, 107, 3738-3744.
31. Piga, A., Gaglioti, C., Fogliacco, E. & Tricta, F. (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassaemia major: a retrospective analysis. Haematologica, 88, 489-496.
32. Saudek, C.D., Hemm, R.M. & Peterson, C.M. (1977) Abnormal glucose tolerance in β-thalassaemia major. Metabolism: Clinical and Experimental, 26, 43-52.
33. Shalev, O., Repka, T., Goldfarb, A., Grinberg, L., Abrahamov, A., Olivieri, N.F., Rachmilewitz, E.A. & Hebbel, R.P. (1995) Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells both in vitro and in vivo. Blood, 86, 2008-2013.
34. Stumvoll, M., Mitrakou, A., Pimenta, W., Jenssen, T., Yki-Jarvinen, H., Van Haeften, T., Renn, W. & Gerich, J. (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care, 23, 295-301.
35. Telfer, P.T., Prestcott, E., Holden, S., Walker, M., Hoffbrand, A.V. & Wonke, B. (2000) Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. British Journal of Haematology, 110, 971-977.
36. WHO Study Group (1985) Diabetes mellitus. World Health Organization Technical Report Series, 727, 1-113.
37. Wonke, B., Wright, C. & Hoffbrand, A.V. (1998) Combined therapy with deferiprone and deferoxamine. British Journal of Haematology, 103, 361-364.
38. Wood, J.C., Otto-Duessel, M., Aguilar, M., Nick, H., Nelson, M.D., Coates, T.D., Pollack, H. & Moats, R. (2005) Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation, 112, 535-543.